Loading...
XJPX4577
Market cap193mUSD
Jan 14, Last price  
2,001.00JPY
1D
0.30%
1Q
-13.49%
Jan 2017
-2.35%
IPO
55.11%
Name

Daito Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XJPX:4577 chart
P/E
9.29
P/S
0.65
EPS
215.46
Div Yield, %
2.96%
Shrs. gr., 5y
2.65%
Rev. gr., 5y
2.66%
Revenues
46.90b
+3.98%
21,460,675,00022,679,543,00025,218,380,00027,149,438,00028,959,211,00031,202,240,00034,062,366,00036,331,198,00037,973,361,00039,883,625,00041,135,053,00044,997,108,00048,709,171,00043,464,000,00045,101,000,00046,895,000,000
Net income
3.30b
-8.47%
692,964,000752,385,000990,619,0001,389,140,0001,786,636,0001,811,396,0002,246,122,0002,566,419,0002,656,281,0003,041,941,0003,513,028,0003,944,714,0004,246,000,0004,668,000,0003,600,000,0003,295,000,000
CFO
5.18b
+24.72%
1,020,926,0002,167,203,0002,829,083,0003,342,888,0002,541,424,0002,744,650,0003,739,312,0002,948,858,0005,069,743,0005,465,342,0006,888,157,0004,306,265,0005,182,527,0004,370,000,0004,155,000,0005,182,000,000
Dividend
May 29, 20250 JPY/sh

Profile

Daito Pharmaceutical Co.,Ltd. manufactures and sells pharmaceutical products worldwide. The company offers various active pharmaceutical ingredients and intermediates, prescription drugs, OTC drugs, and home-delivery medicines; formulations in various forms, such as tablets, capsules, troches, granules, and powders; and contract manufacturing services for formulations of medicinal products to pharmaceutical companies. It also sells health food products. The company was formerly known as Daito Corporation and changed its name to Daito Pharmaceutical Co.,Ltd. in 1992. Daito Pharmaceutical Co.,Ltd. was incorporated in 1942 and is headquartered in Toyama, Japan.
URL
https://www.daitonet.co.jp/
IPO date
Mar 24, 2010
Employees
1,011
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑052023‑052022‑052021‑052020‑052019‑052018‑052017‑052016‑052015‑05
Income
Revenues
46,895,000
3.98%
45,101,000
3.77%
43,464,000
-10.77%
Cost of revenue
39,405,000
36,635,000
33,754,000
Unusual Expense (Income)
NOPBT
7,490,000
8,466,000
9,710,000
NOPBT Margin
15.97%
18.77%
22.34%
Operating Taxes
1,040,000
1,549,000
2,092,000
Tax Rate
13.89%
18.30%
21.54%
NOPAT
6,450,000
6,917,000
7,618,000
Net income
3,295,000
-8.47%
3,600,000
-22.88%
4,668,000
9.94%
Dividends
(907,000)
(931,000)
(660,000)
Dividend yield
2.60%
2.81%
1.81%
Proceeds from repurchase of equity
(1,176,000)
192,000
3,013,000
BB yield
3.37%
-0.58%
-8.27%
Debt
Debt current
2,374,000
1,513,000
1,200,000
Long-term debt
8,296,000
3,537,000
2,247,000
Deferred revenue
5,000
507,000
755,000
Other long-term liabilities
562,000
170,000
165,000
Net debt
4,755,000
(1,726,000)
(3,892,000)
Cash flow
Cash from operating activities
5,182,000
4,155,000
4,370,000
CAPEX
(6,276,000)
(5,556,000)
(4,733,000)
Cash from investing activities
(5,930,000)
(5,566,000)
(4,400,000)
Cash from financing activities
(183,000)
616,000
989,000
FCF
659,000
1,714,000
2,788,364
Balance
Cash
2,727,000
3,607,000
4,381,000
Long term investments
3,188,000
3,169,000
2,958,000
Excess cash
3,570,250
4,520,950
5,165,800
Stockholders' equity
46,181,000
93,163,000
87,040,000
Invested Capital
57,974,750
51,526,050
45,470,200
ROIC
11.78%
14.26%
17.60%
ROCE
12.16%
15.10%
19.16%
EV
Common stock shares outstanding
15,691
15,828
15,310
Price
2,226.00
6.32%
2,093.64
-12.00%
2,379.09
-20.21%
Market cap
34,928,166
5.40%
33,137,920
-9.02%
36,423,387
-18.66%
EV
39,879,166
80,851,920
79,171,387
EBITDA
11,149,000
12,336,000
13,023,000
EV/EBITDA
3.58
6.55
6.08
Interest
41,000
12,000
9,000
Interest/NOPBT
0.55%
0.14%
0.09%